Carna Biosciences, Inc. (TYO:4572)
301.00
-11.00 (-3.53%)
At close: Feb 6, 2026
Carna Biosciences Revenue
Carna Biosciences had revenue of 144.33M JPY in the quarter ending September 30, 2025, a decrease of -16.19%. This brings the company's revenue in the last twelve months to 544.45M, down -61.14% year-over-year. In the year 2024, Carna Biosciences had annual revenue of 636.00M, down -60.86%.
Revenue (ttm)
544.45M
Revenue Growth
-61.14%
P/S Ratio
10.58
Revenue / Employee
8.64M
Employees
63
Market Cap
5.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 636.00M | -989.00M | -60.86% |
| Dec 31, 2023 | 1.63B | 239.00M | 17.24% |
| Dec 31, 2022 | 1.39B | -631.00M | -31.28% |
| Dec 31, 2021 | 2.02B | 884.00M | 78.02% |
| Dec 31, 2020 | 1.13B | -2.07B | -64.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Transgenic Group | 12.92B |
| Linical | 9.87B |
| Kohjin Bio | 5.20B |
| Soiken Holdings | 4.87B |
| OncoTherapy Science | 956.00M |
| PRISM BioLab Co.,LTD | 677.33M |
| D. Western Therapeutics Institute | 419.76M |
| Noile-Immune Biotech | 7.00M |